Funding transnational collaborative research through joint transnational calls is one of the major objectives of E-Rare. This is the most important and effective joint activity to enhance the cooperation between European scientists working on rare diseases and thus reducing the fragmentation of research in this field. E-Rare launches calls on a yearly basis. The topic and eligibility criteria are specified every year and therefore may vary from one call to the other.

France
Israel
Canada
RNA-ALS
Dysregulation of RNA in the pathogenesis of ALS

Project Coordinator

McGill University
Montreal
Canada (Québec)

Partners

Eran Hornstein Weitzmann Institute of Science Rehovot, Israel
Edor Kabashi Centre de Recherche de l’Institut du Cerveau et de la Moelle Épinière (CRICM) Paris, France
Michael Strong Western University London, Canada

Amyotrophic lateral sclerosis (ALS) is a devastating, neurodegenerative disorder characterized by muscle weakness progressing to paralysis as a consequence of dysfunction and death of motor neurons. A striking number of genes implicated in pathogenesis encode proteins with functions in RNA metabolism. To address the mechanisms involved and identify common therapeutic targets, we have formed a unique transnational consortium of investigators with expertise in clinical neurology and pathology, RNA metabolism, motor neuron cell biology and experimental modeling. The specific aims build on strong preliminary evidence that miRNAs, regulators of protein-encoding RNAs, are aberrantly expressed in motor neurons in ALS and that neurofilaments are a disease-relevant target. We will characterise and determine the relative role of the miRNAs regulating stability of mRNAs encoding the neurofilament-forming proteins. How their expression is affected in ALS will be defined using autopsy tissue from sporadic and familial ALS patients relative to controls. The function of ALS-relevant miRNAs and consequences of their disruption will be investigated by manipulating their expression in spinal motor neurons in culture, in adult mice and in zebrafish models, and by assessing the impact on multiple functional measures. Finally, we will determine if manipulating key miRNAs is neuroprotective in primary motor neuron culture and zebrafish models of familial ALS. These experiments will establish models and relevant endpoints for future studies to identify novel therapeutics for ALS.

E-Rare 2012 - Created by Toussaint Biger